Dendritic cell-based immunotherapy for multiple myeloma -- review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 821-825, 2009.
Artículo
en Chino
| WPRIM
| ID: wpr-334017
ABSTRACT
Patients with multiple myeloma (MM) have increased constantly in recent years, but treatment for patients with MM is currently unsatisfactory and it is necessary to develop new complementary therapies. Dendritic cells (DCs) are specialized antigen-presenting cells capable of initiating and regulating immune responses. Vaccination with tumor antigen-pulsed DCs has shown to be safe and possesses therapeutic effect against many tumors. In this review, the various types of MM-associated antigens and clinical trials on DC-based immunotherapy in MM are summarized, the development of DC immunotherapy for MM patients in future trials is discussed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Células Dendríticas
/
Vacunas contra el Cáncer
/
Usos Terapéuticos
/
Alergia e Inmunología
/
Inmunoterapia
/
Mieloma Múltiple
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS